GLP-1 Services Crunch: Which Pharma Services Vendors Scale to 10M Patients?

Thesis

GLP-1 is the stress test for high-volume specialty-lite commercialization. The class combines specialty economics, primary-care prescribing, retail and mail-order fulfillment, extreme PA volume, obesity coverage friction, DTC cash-pay channels, IRA/MFP exposure, and supply-allocation history in one market. Traditional specialty infrastructure was built for tens of thousands of patients; GLP-1 access workflows must operate at millions-of-patients scale (page raw research; Drug Channels specialty pharmacy market analysis; FDA compounding shortage materials).

The vendor-selection thesis is that no single platform owns the whole GLP-1 services stack. CoverMyMeds and AI PA vendors matter for authorization throughput; ConnectiveRx, EVERSANA, AssistRx, CareMetx, and Phil matter for hub/digital-access execution; CVS, Accredo, OptumRx, retail, and DTC channels matter for fulfillment; Valeris and copay/GTN platforms matter for accumulator and payer-type segmentation. Winners are vendors that can handle volume, automation, retail/DTC routing, and payer-type bifurcation rather than vendors optimized only for classic rare or oncology specialty programs.

TL;DR Executive Summary

• The volume problem is structural. Traditional specialty hubs serve 10,000-50,000 patient programs. GLP-1 obesity programs need infrastructure for millions. FTE-based hub models face margin compression; digital-first and AI-automated approaches have a structural advantage.
• No single vendor dominates across all GLP-1 service categories. CoverMyMeds leads prior authorization, ConnectiveRx has the deepest direct GLP-1 hub experience via Novo Nordisk, EVERSANA has the infrastructure scale, Phil is the digital-first disruptor, and Valeris leads on accumulator detection. GLP-1 manufacturers run multi-vendor stacks.
• Channel is shifting from specialty to retail to DTC. Specialty pharmacies (CVS Specialty, Accredo, OptumRx) still dominate injectable cold-chain volume, but retail (CVS, Walgreens, Costco, Amazon Pharmacy) and manufacturer DTC (NovoCare Pharmacy, LillyDirect) are capturing growing share. Oral GLP-1s will accelerate the retail shift.
• The 2027 IRA reset rewires economics. Semaglutide’s Maximum Fair Price takes effect January 1, 2027 at $274/month — a 71% discount from the $959/month list price. Medicare copay assistance demand collapses. SP dispensing margins compress. Manufacturer services budgets pivot from copay administration to adherence.
• Compounding ends, but not cleanly. The FDA shortage ended February 2025; 503A/503B compounders had to cease by April-May 2025. ~1.5M patients on compounded semaglutide had to be redirected, driving manufacturer DTC cash-pay programs.
• GLP-1 is the stress test for the next wave. The vendors that win here set the template for high-volume primary-care-specialty launches in oral obesity, cardiometabolic combinations, and multi-agonist follow-ons.

Market Size, Patient Volume, and the Next Five Years

GLP-1 receptor agonists are the fastest-growing drug class in pharmaceutical history. Novo Nordisk’s semaglutide franchise generated approximately $29.3B in 2024 revenue (Ozempic $17.47B, Wegovy $8.45B, Rybelsus $3.38B). Eli Lilly’s tirzepatide franchise generated $16.46B in 2024 (Mounjaro $11.54B, Zepbound $4.92B) and surged to approximately $36.5B in 2025 — overtaking the Novo portfolio and driving Lilly’s total revenue to $65.2B (+45% year-over-year). Lilly has guided to $80-83B for 2026; Novo has guided to a 5-13% decline.

Patient volume is the number that matters for services infrastructure. By February 2026, 20-25M Americans were on GLP-1 therapy. CDC data show 26.5% of adults with diagnosed Type 2 diabetes (~6.9M people) use GLP-1 injectables; Gallup/Statista estimates 12.4% of US adults report using GLP-1s for weight loss. HealthVerity data show 1 in 4 GLP-1 patients in its 19.1M-patient dataset do not carry a T2DM diagnosis — confirming substantial off-label/weight-loss utilization. Analysts project 1 in 10 Americans will be on a GLP-1 by 2030.

The compounding disruption redirected roughly 1.5M patients. During the semaglutide shortage (March 2022-February 2025), 503A and 503B compounders produced semaglutide copies at $100-$400/month vs. $900-$1,350/month branded. Hims & Hers, Mochi Health, and Fella Health built significant businesses around this channel, with an estimated 1.5M+ patients served. When FDA ended the semaglutide shortage in February 2025, enforcement was swift: 503A cessation by April 22, 2025; 503B by May 22, 2025; tirzepatide deadline in May 2025. Novo has filed 132 complaints across 40 states with 44 permanent injunctions. Manufacturers responded with DTC cash-pay: NovoCare Pharmacy ($499/month direct-ship) and a Novo/CVS retail cash program ($499/month across 9,000+ locations).

The next wave is already visible. Oral Wegovy (semaglutide 25mg tablet) launched January 2026 at $149-$299/month self-pay; 73% of PCPs and 78% of endocrinologists wrote within the first month, and over 70% of early prescriptions went to patients new to the brand. Eli Lilly’s orforglipron — a small-molecule non-peptide oral GLP-1 with no dietary restrictions — has an expected FDA decision in Q2 2026 after demonstrating superiority over oral semaglutide in Phase 3 (A1c -1.9% vs. -1.4%; weight loss -8.2% vs. -5.3%). Lilly’s retatrutide (triple GLP-1/GIP/glucagon agonist) showed nearly 30% body weight loss at 68 weeks in Phase 2 vs. tirzepatide’s ~20% and semaglutide’s ~14%; Phase 3 readout is expected in 2026.

The Services Bottlenecks

Every services category built for specialty drugs is under stress. The five critical bottlenecks:

1. Hub capacity. Traditional hubs were architected for 10,000-50,000 patient specialty programs staffed by call-center FTEs. GLP-1 obesity demands infrastructure for millions. FTE-based pricing models (ConnectiveRx has historically been ~$55K/head) face margin compression unless vendors automate aggressively. Phil claims to operate at roughly 1/10th the cost of traditional hubs — an advantage that compounds at GLP-1 volume.

2. Prior authorization walls. Every commercial GLP-1 prescription for the obesity indication requires PA, with step therapy attestations, BMI documentation, comorbidity records, and payer-specific forms that vary by drug and indication. This is the highest-volume PA category in US healthcare. Benefit verification complexity compounds: the same molecule (semaglutide) is dispensed under three brand names with three coverage frameworks — Ozempic for T2DM via pharmacy benefit, Wegovy for obesity with separate PA criteria, Rybelsus as oral T2DM — often with different coverage status entirely.

3. Specialty vs. retail dispensing. GLP-1s are “specialty-lite” — cold chain required (36-46°F), high cost, PA required, but no REMS, no limited distribution, PCP-prescribed. Retail absorbed the volume surge but many lose money per script (wholesaler cost at WAC vs. PBM reimbursement averaging ~96% of WAC). Specialty pharmacies are better equipped for cold chain and PA navigation but were not built for PCP-driven, multi-million-patient volume.

4. Copay processing throughput. Weight-management drugs accounted for 46.8% of the total increase in employer drug spend in 2024; GLP-1s represent 10.5% of total annual pharmacy claims for employers in 2025 (up from 6.9% in 2023). Historical copay processors were sized for specialty volumes; GLP-1 commercial redemption is reshaping the economics. PBMs capture approximately $6.5B of manufacturer copay funds annually through accumulator/maximizer programs — GLP-1 programs are a primary target.

5. Shortage and allocation management — a new services category. During the March 2022-February 2025 semaglutide shortage, manufacturers, wholesalers, SPs, and hubs had to operate explicit allocation logic: who gets the next pen injector, which patients are prioritized, how to document compliant distribution. Allocation management as a service barely existed pre-GLP-1. It will be table stakes for the next high-volume constrained launch.

Vendor Landscape by Bottleneck

4a. High-Volume Hub Operators — Who Actually Scales?

The hub vendor question for GLP-1 is not “who has the most features” — it is “who can run a 1M+ patient program without unit-economics collapse.”

Vendor	GLP-1 Readiness	Documented Scale	Key GLP-1 Signal	Key Gap
ConnectiveRx	Medium-High	~90M patients/year supported across programs; 2B Rx transactions/year; 1.2M prescriber network	Novo Nordisk is largest client (~13% of revenue) — Ozempic, Rybelsus programs	Hub CRM re-platforming in progress; pharmacy dispensing capability (ConnectiveRx Pharmacy launched September 2025) still early
EVERSANA	High	6,000+ employees; 650+ clients; ACTICS eBV/ePA with 1,500+ payers covering ~90% of US covered lives	Full-stack: owned specialty pharmacy (cold chain), ORCHESTRATE omnichannel	Broad scope may dilute GLP-1 focus; owned SP creates channel bias
CareMetx-owned Lash/TheraCom	High	30-year Lash hub heritage now operating under CareMetx; 100+ programs, 15M+ patients cited in legacy Lash context	McKesson (competitor) has more visible GLP-1 distribution share via CVS	Post-divestiture integration and current program ownership require diligence
AssistRx	High	430 employees; 61K+ pharmacy network; WCAS capital	CoAssist reduced time-to-therapy from 12.2 to 3.7 days; AllazoHealth AI acquisition (April 2025)	EHR-native model built for specialist prescribers; PCP workflow optimization less proven
Phil	Medium (high growth)	200-500 employees; ~35 programs total	PHIL Direct launched September 2025 with GLP-1 as initial use case; claims 80-90% digital enrollment, 6-week launch	Specialty-lite focus; limited cold-chain experience; capacity constraint
CareMetx	Medium	600+ employees; 2M patients/year; 80+ brands	Digital Hub model; EHR integration	Specialty-focused; PCP workflow and high-volume GLP-1 scale less proven

Key finding. ConnectiveRx has the deepest direct GLP-1 hub experience via Novo Nordisk (explicitly disclosed as largest customer at ~13% of revenue). EVERSANA has the infrastructure scale and payer connectivity (ACTICS connects to 1,500+ payers covering ~90% of US covered lives) and owns its specialty pharmacy for cold-chain integration. Phil is the digital-first disruptor. None of the traditional hub vendors was architecturally built for millions-of-patients scale — all are adapting, and vendors that automate aggressively will outcompete labor-intensive incumbents.

4b. AI / Automated Prior Authorization — The GLP-1 PA Wall

GLP-1 PA volume is the killer use case for AI PA automation — the workflow is high-volume, step-therapy-heavy, and standardizable. AI PA spending grew roughly 10x year-over-year from approximately $10M in 2024 to $100M in 2025. The CMS Interoperability and Prior Authorization Final Rule pulls the regulatory tailwind in: 72-hour expedited / 7-day standard decision deadlines effective January 1, 2026, plus a FHIR-based PA API mandate by January 1, 2027.

Vendor	GLP-1 PA Role	Architecture	Key Metric
CoverMyMeds (McKesson)	Dominant — PCP workflow	EHR-embedded ePA across 350+ EHRs, 50,000+ pharmacies, 950,000+ providers; ~90% of US ePA volume	PAs completed in <5 min electronically vs. days manually; GLP-1 workflow guides integrated at point of prescribing
Infinitus Systems	Strong — voice AI fallback	Voice AI for PA follow-up calls; knowledge graph from 4M+ payer calls; 1,400+ payers, 1,000+ therapies	100M+ minutes of healthcare conversations; 8 of top 10 pharma as customers; 30% faster calls, 10% higher quality than humans (Cencora)
Agadia Systems (PAHub)	Payer-side automation	45+ health plans/PBMs, ~100M lives; intake, review, decisioning	Focus on auto-approval for routine GLP-1 cases
AssistRx ePA	Hub-integrated	AllazoHealth AI (April 2025 acquisition); EHR-native enrollment	CoAssist reduced time-to-therapy from 12.2 to 3.7 days
Neon Health	Emerging — end-to-end	Multi-channel AI workforce (voice, portal, fax, SMS); CareMetx design partner	300% ROI in 3 months, 70% cost reduction per BV (CareMetx case study)
Prime Therapeutics (in-house)	Payer-side benchmark	2 in 3 GLP-1 PAs processed automatically by July 2025	Integrated medical claims data approach

Why CoverMyMeds matters most. GLP-1s are predominantly prescribed by PCPs who rely on embedded EHR workflows rather than specialty hub portals. CoverMyMeds dominates that workflow. Voice AI point-solutions (Infinitus, SuperDial) capture value on the phone-call follow-up layer — critical because the slowest PA bottleneck is the human-to-human payer call — but not the core electronic PA workflow. See our AI prior authorization vendor comparison.

Step therapy is the specific GLP-1 PA challenge. Unlike oncology or rare disease PA, GLP-1 obesity PA revolves around step therapy: proving the patient tried behavioral interventions, failed prior therapies, and meets BMI thresholds with specific comorbidity documentation. Vendors with pre-built step therapy templates and automated clinical evidence extraction from EHR records are structurally advantaged. The 2027 FHIR API mandate rewards early standards compliance.

4c. Specialty Pharmacy / Retail Channel — The Shift Is Real

GLP-1s’ specialty-lite classification created channel tension that is now resolving in favor of retail and manufacturer DTC.

Channel	Position	Key GLP-1 Dynamic
Big 3 PBM SPs — CVS Specialty Pharmacy, Accredo, OptumRx Specialty Pharmacy	Dominant for injectable cold-chain volume today	CVS Caremark/Novo Nordisk exclusive deal (effective July 2025) makes Wegovy the preferred obesity GLP-1 across tens of millions of covered lives, driving Wegovy volume to CVS. Express Scripts offers both Wegovy and Zepbound as preferred. OptumRx: both Tier 2 with PA and QL; added Wegovy for CV indication January 2025.
Retail chain pharmacies — CVS retail, Walgreens, Costco, Amazon Pharmacy, grocery	Growing share, often at thin/negative margin	Wholesaler acquisition at ~WAC vs. PBM reimbursement averaging ~96% of WAC → negative dispensing spread for many retail scripts. Amazon Pharmacy leverages Prime logistics; Costco undercuts on cash pay.
Mail-order / Big 3 affiliated mail	High-volume monthly refills	Patients prefer home delivery of monthly pens. CVS Caremark, Express Scripts Pharmacy, Optum Rx mail channels growing.
Manufacturer DTC — NovoCare Pharmacy, LillyDirect	New entrant capturing ex-compounded patients	NovoCare launched March 2025 at $499/month direct-ship cash pay. LillyDirect routes Zepbound prescribing through contracted telehealth partners. Direct patient data, bypass of PBM rebate/accumulator dynamics, exclusion of wholesaler channel.
Independent telehealth — Hims & Hers, Ro, Noom, GoodRx	Consumer-facing, cash-pay anchor	Built $3B+ GLP-1 vertical during the shortage largely on compounded product. Post-shortage, renegotiating supply — some pivoting to branded via manufacturer DTC integrations.

Why specialty-only SPs are losing relative share for GLP-1. Specialty pharmacies were built for limited distribution, REMS management, specialist prescribers, and high-touch support for 10,000-100,000 patient programs. GLP-1s dispense in the millions, are PCP-prescribed, and require monthly refills that favor mail-order or retail. The Big 3 PBM-owned SPs retain volume through PBM mail-order channels and the CVS-Novo exclusive. Pure-play specialty-only SPs without retail or mail-order scale (see our Big 3 PBM specialty pharmacy comparison) are progressively sidelined.

The oral GLP-1 transition accelerates the retail shift. Oral Wegovy launched January 2026 at $149-$299/month self-pay. Orforglipron (FDA decision expected Q2 2026) would eliminate cold chain entirely. Oral formulations shift dispensing decisively toward retail, grocery, and cash-pay channels. Specialty pharmacies should invest in adherence and payer-navigation services rather than rely on GLP-1 dispensing volume growth.

4d. Digital-First / DTC / Telehealth Hubs — A New Vendor Category

Legacy hub players did not build this category. It emerged during the 2022-2025 shortage and is now structurally positioned to absorb high-volume primary-care-specialty launches.

Manufacturer-sponsored digital hubs. Phil launched PHIL Direct in September 2025 with GLP-1 as the anchor use case — integrating e-prescribing, benefit verification, copay enrollment, and home delivery through a pharmacy network. Phil claims 80-90% digital enrollment rates and 6-week launch vs. months for legacy hubs; the pricing model (roughly $5-15 per patient per month plus pharmacy margin) is structurally lower than FTE-heavy specialty hubs.

Manufacturer-owned DTC pharmacies. NovoCare Pharmacy (March 2025) ships Wegovy direct-to-patient at $499/month cash pay. LillyDirect (launched January 2024, expanded 2025) routes Zepbound prescribing through contracted telehealth partners with home delivery. Both channels give manufacturers direct patient data, bypass PBM rebate/accumulator dynamics, and capture self-pay patients who would otherwise leak to compounders or telehealth competitors. Neither fully replaces pharmacy benefit coverage but both capture meaningful uninsured, underinsured, and cash-pay volume.

Independent telehealth platforms. Hims & Hers, Ro, and Noom each built weight-loss verticals generating hundreds of millions in revenue during the shortage. They aggregate patients across brands, can steer toward generic or compounded alternatives when available, and bring consumer marketing capability traditional hubs lack. GoodRx operates a marketplace model combining prescription discount cards with GoodRx Care telehealth — relevant for cash-pay GLP-1 patients.

Why this is a new vendor category. Legacy hub players are architecturally call-center + EHR + specialty pharmacy routing — none own direct consumer relationships, outbound marketing, or app-native patient engagement at scale. For the next high-volume primary-care-specialty launch (oral obesity, cardiometabolic, multi-agonists), the digital-first hub layer is no longer optional. The strategic question for manufacturers is whether to contract with a third-party (Phil, CaryHealth) or build DTC in-house (NovoCare, LillyDirect).

4e. Compounding / 503B — The Disruptor That Ended

The compounding chapter illustrates how fast pharma services infrastructure can be rewired by regulatory action. During the 2022-2025 semaglutide shortage, 503A and 503B compounders (Empower Pharmacy was the highest-profile 503B) produced compounded semaglutide at $100-$400/month vs. $900-$1,350/month for branded. API cost at compounding scale was approximately $20-$50/month — 60-80% gross margin to the compounder + telehealth partner.

The unwind was fast. FDA ended the semaglutide shortage designation in February 2025; 503A pharmacies had to cease by April 22, 2025 and 503B outsourcing facilities by May 22, 2025. Tirzepatide shortage ended with a May 2025 compounder deadline. Novo Nordisk filed 132 complaints across 40 states, obtaining 44 permanent injunctions. FDA received 455+ adverse event reports for compounded semaglutide and 320+ for compounded tirzepatide.

Pharma services implications. Roughly 1.5M patients on compounded semaglutide had to be redirected. Telehealth platforms (Hims, Ro, Mochi) rebuilt supply chains. For hub services, the open questions are copay program eligibility for patients transitioning from compounded to branded, PA documentation gaps (compounded prescriptions rarely generated structured EHR records that branded PA now requires), and channel-integrity policing of the boundary between legitimate individual-patient compounding and unauthorized copies.

The compounding landscape continues to evolve — date-stamp all claims. As of April 2026, the major 503B semaglutide/tirzepatide production cessation orders are in effect, but litigation and state-level variation remain active.

4f. Copay Processors — Commercial Volume vs. Medicare Reset

GLP-1 affordability is the defining patient access challenge. Manufacturer savings programs reduce commercial patient cost to as low as $25/month; annual gross cost per patient runs $12,000-$17,000 before rebates. List prices range $900-$1,350/month; net prices after rebates have been estimated at $617-$766/month for Wegovy per JAMA analysis. Medicare/Medicaid patients are explicitly excluded from commercial copay cards.

High-volume copay processing. ConnectiveRx processes copay cards at approximately $2.50 per redemption at scale with ~71% gross margins in its copay segment — the benchmark for commercial GLP-1 throughput. Valeris (PharmaCord + Mercalis, merged May 2025 under Permira) holds the strongest position on accumulator/maximizer detection with proprietary algorithms inherited from TrialCard (9 US patents) and first-in-market medical benefit maximizer detection via Policy Reporter (February 2026). Phil bifurcates program logic by payer type natively — a capability that matters as manufacturers operate commercial and Medicare strategies simultaneously.

Accumulator/maximizer exposure. 50-60% of commercially insured lives (2025-2026) have accumulator or maximizer programs applied to specialty prescriptions, redirecting $4.8B in copay assistance to PBMs in 2023. GLP-1 programs are a primary target. Only 26 states + DC/PR have anti-accumulator laws, covering ~17% of the commercial market — the other 83% are exposed.

The Part D reset. The $2,000 annual Part D OOP cap ($2,100 indexed for 2026) combined with the Manufacturer Discount Program (10% initial + 20% catastrophic) rewires Medicare copay economics. Medicare copay card maximums should drop to $2,000-$3,000 from $10,000-$20,000 — reducing waste and redirecting budget to commercial accumulator mitigation. Hub vendors must bifurcate workflows by payer type: Medicare patients follow M3P + foundation + adherence; commercial patients follow copay card + accumulator detection + bridge programs. For the broader economic modeling and 2025 market-update context, see our market sizing deep dive.

IRA / Medicare Implications — The 2027 Semaglutide Reset

Semaglutide was selected for IRA Round 2. The Maximum Fair Price for Ozempic/Wegovy/Rybelsus takes effect January 1, 2027 at $274/month — a 71% discount from the $959/month list price. Given $15.16B in 2024 Part D gross costs for semaglutide, this is the largest single dollar-impact drug in the entire negotiation program. Round 3 (announced January 2026; effective January 2028) includes Lilly’s Trulicity, an older GLP-1, compounding the negotiated-pricing footprint across the class.

Medicare obesity coverage begins mid-2026. A November 2025 policy change established Medicare Part D obesity coverage starting mid-2026, with beneficiary copays capped at $50/month and injectable pricing set at approximately $245/month — a landmark reversal of the prior Part D prohibition on obesity-only drugs. This dramatically expands the Medicare GLP-1 eligible population at a negotiated-equivalent price point.

Vendor impact of the 2027 reset.

Vendor Category	Pre-2027	Post-January 2027
Medicare semaglutide copay cards	$10K-$20K annual maximums; accumulator-exposed	$2K-$3K maximums; largely moot under $2,100 OOP cap + MFP
Semaglutide hub FTEs	Heavy copay admin focus	Pivot to M3P enrollment, adherence, foundation routing
Semaglutide SP dispensing margins	Percentage-based on $959/mo gross	Percentage-based on $274/mo gross — ~70% dollar compression per script
Semaglutide adherence programs	Manufacturer funded at scale	Even more critical — manufacturer bears MDP cost whether patient stays on therapy, so retention ROI rises

Commercial GLP-1 economics are untouched by the 2027 reset. The MFP applies only to Medicare Part D. Commercial pricing, Lilly’s tirzepatide products (not in Round 2 or Round 3), and self-pay/DTC channels continue at list or negotiated commercial rates. Manufacturer copay programs for commercially insured GLP-1 patients remain critical — and accumulator/maximizer detection becomes the key vendor differentiator. The long arc: hub vendors that can route patients across Medicare M3P, commercial copay, foundation PAP, and manufacturer DTC cash-pay on a single tech stack with payer-type segmentation gain a structural advantage.

The Services Thesis

Vendors that win at GLP-1 scale share four characteristics. (1) Proven high-volume infrastructure — ConnectiveRx at ~90M patients/year, EVERSANA ACTICS covering ~90% of US covered lives, CoverMyMeds at ~90% of US ePA volume; scale that was overkill for rare disease programs is the floor for GLP-1. (2) AI-PA native or augmented — GLP-1 PA volume cannot be worked manually at margin. (3) Retail channel integration — the SP-to-retail shift is structural and accelerates with oral formulations. (4) DTC hub operator experience — Phil, NovoCare, and LillyDirect have built capabilities legacy hubs do not own: direct patient acquisition, cash-pay flows, manufacturer DTC channel integration.

Vendors at risk. Traditional specialty-only SPs without retail or PBM-scale mail-order channels. Mid-scale hubs without automation — FTE-based hubs at GLP-1 volume face margin compression the longer they run manual workflows. Legacy copay processors without accumulator detection or payer-type segmentation — commercial copay complexity is rising as accumulators expand while Medicare copay economics collapse under the 2027 reset.

What this portends for the next primary-care-specialty wave. Oral obesity drugs (oral Wegovy launched January 2026; orforglipron FDA decision expected Q2 2026), cardiometabolic GLP-1 combinations, and multi-agonist follow-ons (retatrutide in Phase 3) will land into a services infrastructure still being rewired. Manufacturers planning 2027-2029 launches should assume a two-hub architecture — traditional hub for injectable/clinical-touch programs plus a digital-first orchestration layer for oral/retail channels — plus AI-PA automation as table stakes, plus manufacturer DTC capability whether built in-house (NovoCare, LillyDirect) or contracted (Phil, CaryHealth). The vendors that win this stress test set the template for the rest of the decade.

Implications

Manufacturers should design GLP-1 service stacks around volume segmentation. Commercial obesity, T2DM, Medicare, self-pay/DTC, compounded-to-branded transitions, and oral formulations each need different PA, copay, pharmacy, adherence, and data workflows. A single classic hub may still be necessary for exceptions and complex patient support, but it should sit alongside digital-first intake, ePA automation, retail/mail routing, and DTC cash-pay capability.

Vendor contracts should include explicit volume economics. FTE-based pricing can break at GLP-1 scale; per-transaction and per-patient pricing need caps, automation pass-throughs, and surge provisions. The highest-value diligence questions are whether the vendor can keep PA turnaround, first-fill conversion, refill adherence, accumulator detection, and patient status reporting stable during volume spikes, shortages, formulary shifts, and the 2027 semaglutide MFP reset.

Operating Model for a GLP-1 Vendor Stack

A scaled GLP-1 program should be designed as a stack rather than a single-vendor award:

Layer	Core job	Procurement implication
Embedded ePA	Capture PCP prescriptions and payer criteria at the point of prescribing	CoverMyMeds or similar EHR-native coverage is usually foundational.
AI follow-up / exception handling	Work the phone, portal, fax, and status-follow-up volume that ePA does not resolve	Voice AI and hub automation should be evaluated on cost per resolved case, not demos.
Digital hub / DTC orchestration	Route commercial, Medicare, cash-pay, and excluded-benefit patients without call-center overload	Phil-style or manufacturer-owned DTC models matter most for obesity and oral formulations.
Retail / mail fulfillment	Dispense at monthly refill scale with cold-chain or oral-therapy readiness	Specialty-only networks are insufficient once retail and cash-pay channels dominate.
Copay / accumulator intelligence	Protect commercial affordability budget and detect maximizer leakage	Vendor must segment Medicare, commercial, self-pay, and employer carve-out logic.
Supply allocation analytics	Manage shortages, starter-dose availability, and refill continuity	A high-volume class needs allocation rules before shortages recur.

The key diligence metric is unit economics at scale. A vendor that looks adequate at 50,000 specialty patients may fail at 1 million GLP-1 patients if every unresolved PA, abandoned referral, shortage exception, or copay inquiry becomes a human touch.

Vendor Ranking: Top GLP-1 Services Providers

Rank	Vendor	Best For	Key Credential
1	CoverMyMeds	GLP-1 prior authorization at PCP scale	EHR-embedded ePA across 350+ EHRs, 950K+ prescribers, ~90% of US ePA volume; <5 min electronic PA vs. days manually
2	ConnectiveRx	High-volume hub operations with proven GLP-1 experience	Novo Nordisk is largest client (~13% of revenue — Ozempic, Rybelsus); ~90M patients/year supported across programs
3	EVERSANA	Full-stack GLP-1 infrastructure	ACTICS covers 1,500+ payers / ~90% of US covered lives; owned cold-chain specialty pharmacy; 6,000+ employees
4	Phil	Digital-first DTC/DTP hub for high-volume launches	PHIL Direct launched September 2025 with GLP-1 as initial use case; claims 80-90% digital enrollment, 6-week launch
5	Infinitus Systems	Voice-AI automation of GLP-1 PA follow-up calls	4M+ payer calls in knowledge graph; 1,400+ payers, 1,000+ therapies; 8 of top 10 pharma as customers
6	CVS Specialty Pharmacy	Integrated retail + specialty + PBM distribution for Wegovy	CVS Caremark/Novo Nordisk exclusive deal (July 2025) preferences Wegovy across tens of millions of lives; 9,000+ retail locations running Novo $499/month cash program
7	AssistRx	Tech-forward enrollment for oral GLP-1 launches	CoAssist reduced time-to-therapy from 12.2 to 3.7 days; AllazoHealth AI acquisition (April 2025); 61K+ pharmacy network

Honorable mentions. Valeris for strongest commercial accumulator/maximizer detection. Accredo / Evernorth as a PBM-integrated Evernorth-owned SP with significant injectable GLP-1 volume through Express Scripts mail. OptumRx Specialty Pharmacy with both Wegovy and Zepbound on formulary and 127M+ PBM members. Walgreens Specialty Pharmacy for retail + specialty dual-channel infrastructure. GoodRx for cash-pay price discovery and marketplace access. Sonexus (Cardinal Health) and CareMetx-owned Lash/TheraCom as traditional full-stack hub operators — credible at scale but with less explicit GLP-1 positioning.

Cross-References

Related Rx Almanac analyses.

• Hub Services Market Analysis — U.S. hub services market sizing, competitive tiers, and M&A
• Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA — Head-to-head on the four major specialist hubs
• AI Prior Authorization Vendors — Infinitus vs SuperDial vs Neon Health vs Coral AI comparison
• Big 3 PBM Specialty Pharmacies — Accredo vs CVS Specialty vs OptumRx
• ConnectiveRx profile — hub and copay processing profile
• Pharma Services Market Sizing — Category-by-category TAM, CAGR, and 2025 market-update context

Category pages.

• Hub Services
• Specialty Pharmacies
• Reimbursement & Prior Authorization
• Copay & Financial Assistance

Analysis compiled April 2026. GLP-1 market figures synthesized from Novo Nordisk and Eli Lilly earnings reports, BCC Research, CDC, CMS, HealthVerity, EBRI, JAMA, Gallup/Statista, Drug Channels, IQVIA, and public vendor disclosures. Vendor GLP-1 capabilities inferred from general capabilities and known client relationships; no program-specific disclosures obtained from manufacturer-vendor contracts. The compounding regulatory landscape remains active — April 2026 snapshot may evolve with ongoing litigation and state-level variation. IRA negotiated pricing for semaglutide effective January 1, 2027; Medicare obesity coverage effective mid-2026. Oral GLP-1 pipeline (orforglipron FDA decision) and multi-agonist readouts (retatrutide Phase 3) may shift competitive dynamics before 2027 implementation.